Literature DB >> 2120741

Adenocarcinoma of the prostate treated with external-beam radiation therapy: 5-year minimum follow-up.

R J Amdur1, J T Parsons, L T Fitzgerald, R R Million.   

Abstract

This is a retrospective analysis of 225 patients with localized adenocarcinoma of the prostate who were treated with continuous-course external-beam radiation therapy at the University of Florida between October 1964 and August 1982. All patients were treated 5 or more years prior to the date of analysis, and 30% were eligible for 10-year follow-up. Hormonal treatment was used only in the management of recurrent disease. Ten-year results by stage were as follows: local control--A, 96%; B1, 92%; B2, 51%; C1, 57%; C2, 76%. Relapse-free survival--A, 96%; B1, 58%; B2, 38%; C1, 43%; C2, 61%. Absolute survival--A, 69%; B1, 29%; B2, 47%; C1, 35%; C2, 50%. Freedom from distant metastasis--A, 100%; B1, 55%; B2, 71%; C1, 65%; C2, 77%. Tumor grade was an important prognostic variable in most of the subgroups analyzed. The 5-year rate of distant metastasis was significantly greater in patients with stage C disease when the biopsy was made by transurethral resection of the prostate (TURP) rather than by needle biopsy. In stage B patients, the biopsy method was not prognostically important. For the 48 patients who developed recurrent tumor in the prostate gland, with or without concurrent metastasis, the 5-year absolute survival rate calculated from the date of recurrence was 26%, compared with 10% for the 34 patients who developed distant metastasis alone. Severe complications developed in 5 out of 225 patients (2%) and included three severe rectal injuries, one bladder neck contracture, and one femoral head necrosis. Moderate complications developed in 48 out of 225 patients (21%), with rectosigmoiditis (8%) and hematuria (5%) being the most common problems. For both moderate and severe complications, there was a clear trend toward an increasing complication rate with increasing dose. The method of diagnosis appeared to be a factor in the development of urinary incontinence following irradiation: needle biopsy, 0/106 (0%); TURP, 3/112 (3%); subtotal prostatectomy, 1/7 (needle biopsy versus TURP or prostatectomy, p = 0.076). The frequency of peripheral edema following irradiation was influenced by a history of surgical disruption of the pelvic lymphatics: staging lymphadenectomy, 2/16 (13%), versus no lymphadenectomy, 0/209 (p = 0.005). A comparison with other series is presented.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2120741     DOI: 10.1016/0167-8140(90)90059-6

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  7 in total

Review 1.  Assessment and therapy for voiding dysfunction after prostatectomy.

Authors:  Rodney A Appell
Journal:  Curr Urol Rep       Date:  2007-05       Impact factor: 3.092

2.  Effects of interruptions of external beam radiation therapy on outcomes in patients with prostate cancer.

Authors:  Yanqun Dong; Nicholas G Zaorsky; Tianyu Li; Thomas M Churilla; Rosalia Viterbo; Mark L Sobczak; Marc C Smaldone; David Yt Chen; Robert G Uzzo; Mark A Hallman; Eric M Horwitz
Journal:  J Med Imaging Radiat Oncol       Date:  2017-10-13       Impact factor: 1.735

3.  Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?

Authors:  Shaakir Hasan; Daniel Gorovets; Eric Lehrer; Stanislav Lazarev; Robert H Press; Madhur Garg; Keyur J Mehta; Arpit M Chhabra; J Isabelle Choi; Charles B Simone
Journal:  Clin Transl Radiat Oncol       Date:  2020-11-25

Review 4.  Radiotherapy for t3 prostate cancer.

Authors:  Andrew Bayley; Mary K Gospodarowicz
Journal:  Curr Urol Rep       Date:  2003-06       Impact factor: 2.862

5.  Proliferative response of human prostate tumour xenografts to surgical trauma and the transurethral resection of the prostate controversy.

Authors:  A E Bogden; D LePage; S Zwicker; W Grant; M Silver
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

6.  Urinary function and quality of life after radiotherapy for prostate cancer in patients with prior history of surgical treatment for benign prostatic hyperplasia.

Authors:  Mélanie Guilhen; Christophe Hennequin; Idir Ouzaid; Ingrid Fumagalli; Valentine Martin; Sophie Guillerm; Pierre Mongiat-Artus; Vincent Ravery; François Desgrandchamps; Laurent Quéro
Journal:  Radiat Oncol       Date:  2018-10-24       Impact factor: 3.481

7.  Treatment interruptions affect biochemical failure rates in prostate cancer patients treated with proton beam therapy: Report from the multi-institutional proton collaborative group registry.

Authors:  James E Han; John Chang; Lane Rosen; William Hartsell; Henry Tsai; Jonathan Chen; Mark V Mishra; Daniel Krauss; J Isabelle Choi; Charles B Simone; Shaakir Hasan
Journal:  Clin Transl Radiat Oncol       Date:  2020-10-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.